Ipratropium

HFA aerosol and nebulizer solution are labeled for maintenance bronchospasm associated with COPD, including chronic bronchitis and emphysema. The nebulizer label permits use alone or with other bronchodilators. HFA is not initial treatment of acute bronchospasm needing rapid rescue; do not infer a labeled asthma rescue regimen.

0.03% treats rhinorrhea from allergic or nonallergic perennial rhinitis in adults and children ≥6 years; it does not relieve congestion, sneezing or postnasal drip. 0.06% treats rhinorrhea from common cold or seasonal allergic rhinitis in adults and children ≥5 years; it does not relieve congestion or sneezing. Safety/effectiveness beyond 4 days for cold or 3 weeks for seasonal allergy are unestablished.

HFA: no shaking required; prime with 2 sprays away from face initially and after >3 days unused. Coordinate slow deep inhalation with actuation, hold breath 10 seconds and wait ≥15 seconds between inhalations. Nasal pumps: 7 initial sprays; after >24 hours unused reprime with 2, after >7 days with 7; avoid eyes. Nebulize the complete vial using the prescribed equipment; eye-safe mouthpiece/mask fit matters. The selected nebulizer label permits mixing only with albuterol or metaproterenol when used within 1 hour; safety/stability of other mixtures are unestablished.

Hypersensitivity to ipratropium or selected product ingredients; hypersensitivity to atropine or its derivatives. Nasal labels specify atropine/derivative or ingredient hypersensitivity. Review the actual formulation’s excipients rather than inherit restrictions from an obsolete inhaler.

No boxed warning appears in the selected single-ingredient inhaled or nasal labels. Their maintenance-only limitations, serious allergy, glaucoma and urinary-retention cautions remain clinically important.

Inhaled products can cause dry mouth, unpleasant taste, throat irritation, headache or nausea. Nasal products commonly cause dryness and epistaxis; dry throat and local irritation also occur. Postmarketing reports include serious allergy, ocular effects, urinary retention and palpitations; frequency/causality cannot be determined reliably. Systemic overdose is considered unlikely with intended inhaled/nasal delivery because absorption is limited, but accidental ingestion, excess use or symptomatic exposure still needs professional assessment; no home antidote or reassurance for severe symptoms.

HFA labeling advises avoiding coadministration with other anticholinergic-containing drugs because effects may add. Nasal labels also identify additive anticholinergic interactions, including oral-inhaled ipratropium. Review duplicate inhalers, bladder medicines and other anticholinergic agents with the prescriber.

The nebulizer label describes concomitant beta-agonist use and permits albuterol/metaproterenol admixtures used within 1 hour; this is not permission for every formulation or nebulized drug. HFA has been used with common COPD therapies, but formal interaction studies are limited; drug compatibility is distinct from therapeutic interaction safety.

HFA pediatric safety/effectiveness are unestablished. Nebulizer data do not establish use below 12; nasal thresholds are ≥6 for 0.03% and ≥5 for 0.06%. Do not transfer a nasal pediatric approval to inhalation. HFA trials found no overall older-adult safety/effectiveness difference, but glaucoma, urinary obstruction and interacting medicines still require assessment.

HFA pharmacokinetics have not been studied in renal/hepatic insufficiency. Nebulizer and nasal labels advise caution in these populations because relevant studies are absent. No numerical renal/hepatic adjustment or dialysis supplementation is established by these labels.

HFA systemic exposure is low; published human experience has not identified a drug-associated major-birth-defect or miscarriage signal, but experience is limited. Nebulizer/nasal labels lack adequate controlled pregnancy studies and advise use only when clearly needed. Human milk data are absent or uncertain; HFA expects low milk exposure, while older-format labels advise nursing caution. Consider maternal need and infant risk; do not claim universal pregnancy/breastfeeding safety or use a legacy letter category as a modern conclusion.

A quaternary antimuscarinic that opposes acetylcholine-mediated airway smooth-muscle constriction. Intranasal administration inhibits serous/seromucous gland secretion. Poor membrane penetration limits systemic effects but does not eliminate ocular or urinary toxicity.

HFA is poorly absorbed systemically; elimination half-life is about 2 hours and metabolism includes inactive ester-hydrolysis products. Nasal labels report <20% absorption of an 84 mcg-per-nostril dose; their approximately 1.6-hour terminal half-life was measured after intravenous administration, not a nasal dosing instruction. HFA pulmonary improvement begins around 15 minutes, peaks at 1–2 hours and persists 2–4 hours in many trial patients. Study actuations expressed at the valve are not the current 17 mcg mouthpiece strength.

Assess response, escalating bronchodilator use, device technique, other anticholinergics and glaucoma/urinary symptoms. For nasal therapy, assess rhinorrhea response, dryness, bleeding and duration. No universal drug-level test or laboratory interval is established.

Use the prescribed route and dose. Seek urgent care for severe breathing difficulty or allergy; promptly report eye pain/halos and difficulty urinating. Wash HFA mouthpiece at least weekly after removing canister/cap, with warm running water ≥30 seconds; air-dry completely before replacement. Refill HFA when indicator approaches 40 and discard at 0, even if liquid remains. Nasal blocked tips may be rinsed under warm water about 1 minute, dried and reprimed; do not enlarge the opening. Clean nebulizer according to equipment instructions, keeping mist out of the eyes.

Package

12.9 g canister, 200 actuations; NDC 0597-0087-17.

Device

White mouthpiece, clear sleeve, green cap and approximate actuation indicator.

Delivered dose

17 mcg ipratropium bromide monohydrate from mouthpiece; 21 mcg from valve after priming.

Nebulizer

0.02%, anhydrous 500 mcg in 2.5 mL; preservative-free sterile isotonic solution. Selected carton NDC 60687-394-83.

Nasal 0.03%

21 mcg per 70 microliter spray; 30 mL, 345 sprays; Lupin NDC 70748-336-01.

Nasal 0.06%

42 mcg per 70 microliter spray; 15 mL, 165 sprays; Oceanside NDC 68682-399-15.

Scope

Prescription single-ingredient products; combined albuterol/ipratropium products require their own doses/device review. No current-stock claim.

HFA: 20–25°C, permitted excursions 15–30°C; no puncturing, heat, flame or incineration; use its own mouthpiece. Nebulizer vials: 15–30°C, protect from light and retain unused vials in foil. Nasal 0.03%: tightly closed at 20–25°C; 0.06%: 20–25°C with 15–30°C excursions. Avoid freezing nasal bottles and protect all products from children. Follow actual package expiration, not an invented common opening discard period.